Volume 9, Number 5 Feb/Mar 2003: Scene: US FDA to Become "Proactive on Switches: 2004 Budget Announces Policy Change. Lifecycle: Late Stage Product Life Cycle Options: Ten Case Studies with Five Successes Using Knowledge Synergies™ (Part Two). More ... 

Volume 9, Number 4 Dec 2002/Jan 2003: Lifecycle: Late Stage Product Life Cycle Options: Knowledge Synergies™ Maximum Return on Investment (Part One). Scene: Rx-to-OTC Switch Scorecard Hits New Low in 2003, But 2003 Holds Promise of Progress. More ... 

Volume 9, Number 3 Oct/Nov 2002: Lifecycle: The Potential ‘New Wave’ of Switches in Europe and the UK: Implications for Exclusivity, the Product Lifecycle, Pharmacists and the ‘P’ Class. Scene: Is a Healthcare Reimbursement Inflection Point Ahead? More ... 

Volume 9, Number 1 Jun/Jul 2002: Celebrex wins as Claritin stumbles. Managed care's effective de-reimbursement of entire product classes poses next big external threat. More ...